海科新源(301292.SZ):子公司動力電池高端材料及配套項目正式開工建設
格隆匯7月9日丨海科新源(301292.SZ)公佈,公司子公司山東新蔚源新材料有限公司(以下簡稱"子公司")於2024年7月8日取得建築工程施工許可證,項目正式開工建設。項目建設期一年,預計2025年4月達到試生產條件。
本項目主要定位新能源電池電解液體系內新原料的開發和供應,所生產的電解質鹽、新型添加劑以及新型溶劑均為高附加值的電池材料,佈局該類產品有助於新源公司打通電解液上下游產業鏈並完成一體化佈局,進一步增強公司盈利能力、客户黏性,提升海科新源核心競爭力。產品技術來源為自研或合作開發,具有較強的技術先進性和可靠性,該項目建成後,將對公司經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.